Valneva (NASDAQ: VALN) highlights Lyme vaccine and joins June investor events

Rhea-AI Filing Summary

Valneva SE, a specialty vaccine company, plans active investor outreach in June 2026 across the U.S. and Europe. Senior management will present and hold meetings at the Jefferies Global Healthcare Conference in New York, the Oddo BHF Nextcap Forum (virtual), and the BNP Paribas SMID Cap Conference in Paris.

Discussion topics include Valneva’s marketed travel vaccines and its pipeline, notably LB6V (formerly VLA15), described as the world’s leading Lyme disease vaccine candidate. LB6V is partnered with Pfizer, which reported topline Phase 3 results showing strong efficacy with no safety concerns and is planning regulatory submissions. Valneva will also engage travel medicine professionals as a Gold Sponsor and exhibitor at the NECTM10 conference in Belfast.

Key Terms

Phase 3 results, topline, prophylactic vaccines, forward-looking statements, +2 more

6 terms

Phase 3 results medical

"Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns."

topline medical

"Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns."

prophylactic vaccines medical

"We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases"

forward-looking statements regulatory

"This press release contains certain forward-looking statements relating to the business of Valneva"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

Lyme Disease vaccine candidate medical

"including LB6V (formerly VLA15), the world’s leading Lyme Disease vaccine candidate."

Gold Sponsor other

"where Valneva is a Gold Sponsor and Exhibitor."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 28, 2026

Commission File Number: 001-40377

Valneva SE

(Translation of registrant's name into English)

Îlot Saint-Joseph, Bureaux Convergence

12ter Quai Perrache

69002 Lyon, France

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On May 28, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1. The information contained in this Form 6-K is hereby incorporated by reference into the registrant's registration Statement on Form F-3 (File No. 333-268071).

Exhibit
Exhibit 99.1			Press release dated May 28, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Valneva SE (Registrant)

Date: May 28, 2026

/s/ Thomas Lingelbach

Thomas Lingelbach

Chief Executive Officer and President

Valneva to Participate at U.S. and European Investor Conferences in June

Lyon (France), May 28, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings at several upcoming investor conferences in the United States and Europe in June 2026.

Key topics for discussion include Valneva’s commercial stage vaccines and its differentiated portfolio of vaccine candidates, including LB6V (formerly VLA15), the world’s leading Lyme Disease vaccine candidate. LB6V is partnered with Pfizer, who reported topline Phase 3 results demonstrating strong efficacy with no safety concerns. Pfizer is currently planning submissions to regulatory authorities.

Institutional investors who would like to meet 1on1 with management at any of the conferences below are asked to submit a request to their representative at the respective bank.

Jefferies Global Healthcare Conference

Format:         Fireside chat and investor meetings

Date/ time:         June 3, 11:40am ET

Webcast:    Link. A replay will be available in the “Investor” section of the Valneva website.

Location:        New York

Oddo BHF Nextcap Forum:

Format:        Investor meetings only

Date/ time:        June 12

Location         Virtual

BNP Paribas SMID Cap Conference:

Format:        Investor meetings only

Date/ time:        June 24

Location:         Paris, France

Additionally, the Company will also engage with travel medical professionals during a key European medical conference, where Valneva is a Gold Sponsor and Exhibitor.

10th Northern European Conference on Travel Medicine (NECTM10)

Date/ time:        June 3 - 5

Location:         Belfast, Ireland

Booth #:        4

Symposium:    From Risk to Protection: Real‐World Perspectives on Mosquito‐Borne Diseases; Promotional session; June 5, 12:30pm BST

VALNEVA SE

About Valneva SE

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.

Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world’s most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats. More information is available at www.valneva.com.

Valneva Investor and Media Contacts Laetitia Bachelot-Fontaine VP, Global Communications and European Investor Relations M +33 (0)6 4516 7099 laetitia.bachelotfontaine@valneva.com Joshua Drumm, Ph.D. VP, Global Investor Relations M +001 917 815 4520 joshua.drumm@valneva.com

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to business partnerships and the progress, timing, results and completion of technology transfer and regulatory approvals in additional markets. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as “could,” “should,” “may,” “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

FAQ

What did Valneva (VALN) announce in its latest Form 6-K?

Valneva announced that senior management will participate in several investor conferences in June 2026 and a major travel medicine congress. They will highlight commercial vaccines and key pipeline assets, including LB6V, a Lyme disease vaccine candidate partnered with Pfizer that showed strong Phase 3 efficacy.

Which June 2026 investor conferences will Valneva (VALN) attend?

Valneva plans to attend the Jefferies Global Healthcare Conference in New York, the Oddo BHF Nextcap Forum (virtual), and the BNP Paribas SMID Cap Conference in Paris. Management will present in a fireside chat and hold one-on-one investor meetings across these events.

What is Valneva’s LB6V (formerly VLA15) Lyme disease vaccine candidate?

LB6V is described as the world’s leading Lyme disease vaccine candidate and is partnered with Pfizer. Pfizer reported topline Phase 3 results demonstrating strong efficacy with no safety concerns and is planning submissions to regulatory authorities, positioning this program as a central topic in upcoming discussions.

How is Valneva (VALN) engaging with healthcare professionals in June 2026?

Valneva will be a Gold Sponsor and exhibitor at the 10th Northern European Conference on Travel Medicine (NECTM10) in Belfast. The company is also supporting a symposium on mosquito-borne diseases, offering real-world perspectives on moving from risk to protection for travelers.

What does Valneva (VALN) say about forward-looking statements in this update?

Valneva includes a detailed forward-looking statements disclaimer, noting that expectations about partnerships, clinical progress, technology transfers, and regulatory approvals involve known and unknown risks. It stresses that actual results may differ materially and that it has no obligation to update such statements publicly.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99 EX-99 15.3 KB